Safety and efficacy of cell therapy in psorisis

Phase 1

• Conditions: Psoriasis.; Psoriasis

• Registration Number: IRCT20080728001031N24
• Lead Sponsor: Iranian academic center for education culture and research

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 7 February 2023

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 5

Inclusion Criteria

Chronic plaque psoriasis for at least 6 months
plaque severity of moderate to severe (grade 3-5)
Psoriasis Area Severity Index (PASI) less than 12
No response to standard treatments
No incidence of new lesion or increase in size of previous lesions during past 6 months

Exclusion Criteria

Other types of psoriasis include pustular, erythrodermic, gotate, and drug induced
Immunosuppressive drugs over the past 4 weeks or topical medications other than moisturizing lotions in the 2 past weeks
Severe underlying disease (including liver, kidney and heart failure), increased liver enzymes more than 3 times normal and creatinine more than 2
high and uncontrolled blood pressure
Pregnancy or lactation
diabetes mellitus
Hepatitis B, C or HIV
Patients with immunodeficiency
Patients with malignancy
Disabling disease
Systemic or injection site infection

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Pain. Timepoint: intervention start date up to 6 months. Method of measurement: Pain intensity scale.;Redness severity. Timepoint: intervention start date up to 6 months. Method of measurement: Physical examination.

Secondary Outcome Measures

Name	Time	Method
esion severity (grade 0-5). Timepoint: Before intervention, every week up to 1 month, and every month up to 6 months. Method of measurement: evaluator assessment.